对于某些癌症手术，中心体积与改善患者预后相关。这种关联对于细胞减灭术/加热腹腔化疗 (CRS/HIPEC) 是否成立尚不清楚。鉴于 CRS/HIPEC 的使用迅速扩大，本分析的目的是确定该策略是否存在数量与结果关系。从 2020 年 1 月到 2022 年 12 月，在 Vizient Clinical Database® 中查询了 CRS/HIPEC 病例。 、中等和高容量的指定是通过按病例量对医院进行排序并根据病例总数创建相等的三分位数来进行的。如所示，通过单向方差分析和事后 Tukey 检验进行分析。在 36 个月的研究期间，149 家医院发现了 5165 例病例。低容量中心 (n = 113)、中容量中心 (n = 25) 和高容量中心 (n = 11) 每年的中位数分别为 4、21 和 47 例。大多数病例是阑尾肿瘤（39.3%），其次是妇科肿瘤（20.4%）。各组在年龄、性别、种族、合并症和组织学方面相似。低容量中心更有可能在术后使用 ICU（59.6% vs. 40.5% vs. 36.3%；p = 0.02）。发病率（9.4% vs. 7.1% vs. 9.0%，p = 0.71）、死亡率（0.9% vs. 0.6% vs. 0.7%，p = 0.93）、住院时间（9.3 vs. 9.4 vs. . 10 天，p = 0.83），30 天再入院（5.6% vs. 5.6% vs. 5.6%，p = 1.0），或组间总成本。未发现 CRS/HIPEC 医院容量与术后之间存在关联结果。这些数据表明，在设有 HIPEC 计划的学术医疗中心，常用治疗癌症的结果与医院容量无关。© 2023。外科肿瘤学会。

For some cancer operations, center volume is associated with improved patient outcomes. Whether this association is true for cytoreductive surgery/heated intraperitoneal chemotherapy (CRS/HIPEC) is unclear. Given the rapidly expanding use of CRS/HIPEC, the aim of this analysis was to determine whether a volume-outcome relationship exists for this strategy.The Vizient Clinical Database® was queried for CRS/HIPEC cases from January 2020 through December 2022. Low-, medium-, and high-volume designations were made by sorting hospitals by case volume and creating equal tertiles based on total number of cases. Analysis was performed via one-way ANOVA with post-hoc Tukey test, as indicated.In the 36-month study period, 5165 cases were identified across 149 hospitals. Low- (n = 113), medium- (n = 25), and high-volume (n = 11) centers performed a median of 4, 21, and 47 cases per annum, respectively. Most cases were performed for appendiceal (39.3%) followed by gynecologic neoplasms (20.4%). Groups were similar with respect to age, gender, race, comorbidities, and histology. Low-volume centers were more likely to utilize the ICU post-operatively (59.6% vs. 40.5% vs. 36.3%; p = 0.02). No differences were observed in morbidity (9.4% vs. 7.1% vs. 9.0%, p = 0.71), mortality (0.9% vs. 0.6% vs. 0.7%, p = 0.93), length of stay (9.3 vs. 9.4 vs. 10 days, p = 0.83), 30-day readmissions (5.6% vs. 5.6% vs. 5.6%, p = 1.0), or total cost among groups.No association was found between CRS/HIPEC hospital volume and post-operative outcomes. These data suggest that in academic medical centers with HIPEC programs, outcomes for commonly treated cancers are not associated with hospital volume.© 2023. Society of Surgical Oncology.